SCHEMBL2363464

SCHEMBL2363464

CC(C)C1(C)CCCC(OC[C@H](O)CO)C1

nearest known ligand 0.33

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
HTT P42858 2/20 0.33
KDM4E B2RXH2 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL375499 1.00 MEN1 (0.33) MEN1KMT2AHTTKDM4EL3MBTL1
SCHEMBL119343 1.00 MEN1 (0.33) MEN1KMT2AHTTKDM4EL3MBTL1
SCHEMBL5164194 0.89 MEN1 (0.32) MEN1KMT2AHTT
SCHEMBL6563539 0.87 MEN1 (0.33) MEN1KMT2AHTTKDM4E
SCHEMBL7666136 0.86 MEN1 (0.30) MEN1KMT2AHTT
SCHEMBL4620512 0.83
SCHEMBL17779971 0.82
SCHEMBL6009698 0.82
SCHEMBL248360 0.80
SCHEMBL6139801 0.79 PTPN1 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3031892-B1 A PROCESS FOR MAKING A CONSUMER GOODS PRODUCT COMPRISING A BENEFIT DELIVERY COMPOSITION PROCTER & GAMBLE (US) 2020-02-26 EP disclosed
EP-3144375-B1 A PROCESS FOR MAKING A DETERGENT COMPOSITION PROCTER & GAMBLE (US) 2018-12-26 EP disclosed
EP-2892620-B1 MOUTH RINSES AND TOOTH SENSITIVITY TREATMENT COMPOSITIONS JOHNSON & JOHNSON CONSUMER INC (US) 2018-05-02 EP disclosed
EP-3031893-B1 A PROCESS FOR MAKING A CONSUMER GOODS PRODUCT COMPRISING A BENEFIT DELIVERY COMPOSITION PROCTER & GAMBLE (US) 2017-11-08 EP disclosed
US-20170081620-A1 PROCESS FOR MAKING A DETERGENT COMPOSITION THE PROCTER & GAMBLE COMPANY 2017-03-23 US disclosed
EP-3144375-A1 A PROCESS FOR MAKING A DETERGENT COMPOSITION The Procter and Gamble Company (US) 2017-03-22 EP disclosed
US-20160166492-A1 PROCESS FOR MAKING A BENEFIT DELIVERY COMPOSITION THE PROCTER & GAMBLE COMPANY 2016-06-16 US disclosed
WO-2016094599-A1 A PROCESS FOR MAKING A CONSUMER GOODS PRODUCT COMPRISING A BENEFIT DELIVERY COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 2016-06-16 WO disclosed
US-20160166493-A1 PROCESS FOR MAKING A BENEFIT DELIVERY COMPOSITION THE PROCTER & GAMBLE COMPANY 2016-06-16 US disclosed
WO-2016094600-A1 A PROCESS FOR MAKING A CONSUMER GOODS PRODUCT COMPRISING A BENEFIT DELIVERY COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 2016-06-16 WO disclosed
US-20140113971-A1 Topical NSAID Compositions Having Sensate Component ZHANG JOANNA (US) 2014-04-24 US disclosed
WO-2014039966-A2 MOUTH RINSES AND TOOTH SENSITIVITY TREATMENT COMPOSITIONS JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2014-03-13 WO disclosed
US-20140072519-A1 MOUTH RINSES AND TOOTH SENSITIVITY TREATMENT COMPOSITIONS JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2014-03-13 US disclosed
US-8084050-B2 Menthol for cooling, tingling sansation, guar hydroxypropyltrimonium chloride a cataionic polymer, solubilizer selected from methanol, ethanol, isopropanol, glycerol, ethylene glycol, diethylene glycol, propylene glycol, polypropylene glycol, polyethylene glycol; oral and personal care applications COLGATE-PALMOLIVE COMPANY (US) 2011-12-27 US disclosed
US-20110237674-A1 TOPICAL NSAID COMPOSITIONS HAVING SENSATE COMPONENT NOVARTIS AG (CH) 2011-09-29 US disclosed
EP-2349248-A2 TOPICAL NSAID COMPOSITIONS HAVING SENSATE COMPONENT Novartis AG (CH) 2011-08-03 EP disclosed
WO-2010045415-A2 TOPICAL NSAID COMPOSITIONS HAVING SENSATE COMPONENT NOVARTIS AG (CH) 2010-04-22 WO disclosed
EP-2088993-A1 COMPOSITIONS COMPRISING COMBINATIONS OF SENSATES Colgate-Palmolive Company (US) 2009-08-19 EP disclosed
WO-2008045678-A1 COMPOSITIONS COMPRISING COMBINATIONS OF SENSATES COLGATE- PALMOLIVE COMPANY (US) 2008-04-17 WO disclosed
US-20080089850-A1 Compositions Comprising Combinations of Sensates COLGATE-PALMOLIVE COMPANY 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160166492-A1 PROCESS FOR MAKING A BENEFIT DELIVERY COMPOSITION CETP, FABP4, LIPA MEN1 703/4885KMT2A 3785/4885HTT 964/4885
US-20110237674-A1 TOPICAL NSAID COMPOSITIONS HAVING SENSATE COMPONENT TRPA1, TRPV1, PTGES MEN1 3419/4885KMT2A 4633/4885HTT 3140/4885
US-20140113971-A1 Topical NSAID Compositions Having Sensate Component TRPA1, TRPV1, PTGES MEN1 3419/4885KMT2A 4633/4885HTT 3140/4885
US-20160166493-A1 PROCESS FOR MAKING A BENEFIT DELIVERY COMPOSITION CETP, SCD, SURF4 MEN1 763/4885KMT2A 4016/4885HTT 1753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.